There was no significant difference in the occurrence of thyroidism related to gender or the therapy modality used, even if combination therapy (PD-1 +CTLA-4 or VEGFi) generally seems to be associated with a higher risk of occurrence (data not shown). Here, CTLA4 is linked to thyroiditis.